SOUTH SAN FRANCISCO, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that it will be presenting at two upcoming scientific conferences. Details are as follows:
February 4-8, 2006: The 2006 Miami Nature Biotechnology Winter Symposium -- Angiogenesis in Cancer and Vascular Disease in Miami Beach, Florida
Presentation Time: Tuesday, February 7th Poster Number: T20 Title: “PRK-1 is a Regulator of Endothelial Cell Migration”
February 14-19, 2006: Cancer and Kinases: Lessons from the Clinic (C2) in Santa Fe, New Mexico
Presentation Time: Wednesday, February 15th Poster Number: 120 Title: “Role for the Receptor Tyrosine Kinase Axl in Angiogenesis and Tumor Growth” About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to move one new product candidate for a significant indication into the clinic each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in allergy/asthma, rheumatoid arthritis and cancer.
This press release contains “forward-looking” statements, including statements related to Rigel’s plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “plans,” “intends,” “expects” and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel’s results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel’s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Rigel does not undertake any obligation to update forward-looking statements.
Contact: Raul Rodriguez Phone: 650-624-1302 Email: invrel@rigel.com Media Contact: Carolyn Bumgardner Wang, WeissComm Partners, Inc. Phone: 415-946-1065 Email: carolyn@weisscommpartners.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comRigel Pharmaceuticals, Inc.
CONTACT: Raul Rodriguez of Rigel, +1-650-624-1302, or invrel@rigel.com; ormedia, Carolyn Bumgardner Wang of WeissComm Partners, Inc.,+1-415-946-1065, or carolyn@weisscommpartners.com, for Rigel
Web site: http://www.rigel.com//
